

**BCRFF Portfolio Status as of 12/31/2022**

Description	Opportunity Fund, LP	INOF-III Fund LLC	Total
<b>Committed Capital</b>	<b>\$ 8,000,000</b>	<b>\$810,104</b>	
<b>12/31/2021 FUND RESULTS (Based on Audited Financial Statements)</b>			
<b>Beaver County Retirement Fund Contributions:</b>			
Total Contributions through 12/31/2021	\$ 8,510,376	\$ -	\$ 8,510,376
Return of Capital (Fund Rebalance)	(662,502)	595,194	(67,308)
Re-Invested Gains Into INOF III	-	214,910	214,910
<b>Total Net Contributions as of 12/31/2021</b>	<b>\$ 7,847,874</b>	<b>\$ 810,104</b>	<b>\$ 8,657,977</b>
<b>Distributions:</b>			
Distributed Gains to BCRS	196,029	-	196,029
Reinvested gains into INOF III	214,910	-	214,910
<b>Total Realized Gains /(Losses)</b>	<b>\$ 410,939</b>	<b>\$ -</b>	<b>\$ 410,939</b>
<b>Fair Value Adjustments:</b>			
Novian Health Series A Preferred Stock	\$ 1,148,672	\$ 449,527	\$ 1,598,199
Propel Series B Convertible Preferred Stock	(487,433)	(53,041)	(540,474)
Vizsafe Note Converted to Series A Preferred Stock	2,534,914	217,302	2,752,216
Cognition Therapeutics Series B Preferred Stock	402,220	-	402,220
PennAlt Organics Preferred Series A & Warrants	(288,251)	-	(288,251)
Wenzel Spine, Inc. B-2 Preferred Stock	609,292	-	609,292
<b>Total Fair Value Adjustments</b>	<b>\$ 3,919,414</b>	<b>\$ 613,788</b>	<b>\$ 4,533,202</b>
<b>Accrued Interest:</b>			
Interest Converted to Equity	\$ 322,572.75	\$ 58,348.00	\$ 380,921
FRH Consumer Services (OneLogos) Note	85,601	28,679	114,280
Novian Health Convertible Note	34,059	-	34,059
Propel IT	61,563	-	61,563
Rabble Holdings	20,312	-	20,312
Wenzel Spine	73,115	-	73,115
<b>Total Accrued Interest through 12/31/21</b>	<b>\$ 597,223</b>	<b>\$ 87,027</b>	<b>\$ 684,250</b>
<b>Realized &amp; Unrealized Gains (losses) thru' 2021</b>	<b>\$ 4,927,576</b>	<b>\$ 700,814</b>	<b>\$ 5,628,390</b>
<b>% Gains/(Losses) through 2021</b>	<b>62.79%</b>	<b>86.51%</b>	<b>65.01%</b>
Fund Fees and Third Party Professional Expenses through 12/31/21	(1,311,141)	(89,031)	(1,400,172)
<b>Net Gains/(Losses) in through 12/31/2021</b>	<b>\$ 3,616,435</b>	<b>\$ 611,783</b>	<b>\$ 4,228,218</b>
<b>% Gains/(Losses) through 2021</b>	<b>46.08%</b>	<b>75.52%</b>	<b>48.84%</b>
<b>Portfolio Value Including Fees and Expenses (Assets at Market)</b>	<b>\$ 11,053,369</b>	<b>\$ 1,421,887</b>	<b>\$ 12,475,256</b>

Note: The Distributions of Gains of \$410,939 are not included in the Total Portfolio Value.

**BCRFF Portfolio Status as of 12/31/2022**

Description	Opportunity Fund, LP	INOF-III Fund LLC	Total
<b>FISCAL YEAR 2022 FUND ACTIVITY</b>			
<b>Beaver County Retirement Fund Contributions:</b>			
Net Contributions as of 12/31/2021	\$ 7,847,874	\$ 810,104	\$ 8,657,977
Contributions in Fiscal Year 2022	-	-	-
<b>Total Net Contributions as of 12/31/2022</b>	<b>\$ 7,847,874</b>	<b>\$ 810,104</b>	<b>\$ 8,657,977</b>
<b>Gains/(Losses) in 2022:</b>			
<b>Realized Gains /(Losses):</b>			
Distribution of Gain from the Opportunity Fund	-	-	-
<b>Total Realized Gains /(Losses)</b>	<b>\$ -</b>	<b>\$ -</b>	<b>\$ -</b>
<b>Fair Value Adjustments:</b>			
Novian Health Series A Preferred Stock	\$ 408,225	\$ 160,000	\$ 568,225
Propel Series B Convertible Preferred Stock	469,155	50,000	519,155
Vizsafe Note Converted to Series A Preferred Stock	284,082	24,400	308,482
Cognition Therapeutics Series B Preferred Stock	(412,626)	-	(412,626)
Rabble Holdings, Inc. Series A Preferred Stock	37,776	-	37,776
Wenzel Spine, Inc. Series B-2 Preferred Stock	152,323	-	152,323
<b>Total Fair Value Adjustments</b>	<b>\$ 938,935</b>	<b>\$ 234,400</b>	<b>\$ 1,173,335</b>
<b>Accrued Interest:</b>			
Interest Converted to Equity	\$ -	\$ -	\$ -
FRH Consumer Services (OneLogos) Note	12,186	5,661	17,847
Novian Health Convertible Note	69,911	-	69,911
Propel IT	35,339	-	35,339
Rable Holdings	8,286	-	8,286
Wenzel Spine	24,372	-	24,372
<b>Accrued Interest in 2022</b>	<b>\$ 150,094</b>	<b>\$ 5,661</b>	<b>\$ 155,755</b>
<b>* Total Gains/(Losses) in 2022</b>	<b>\$ 1,089,029</b>	<b>\$ 240,061</b>	<b>\$ 1,329,091</b>
<b>% Total Gains/(Losses) in 2022</b>	<b>13.88%</b>	<b>29.63%</b>	<b>15.35%</b>
Fund Fees and Third Party Professional Expenses 2022	\$ (9,492)	\$ (16,202)	\$ (25,694.01)
<b>Net Gains/(Losses) in 2022</b>	<b>\$ 1,079,537</b>	<b>\$ 223,859</b>	<b>\$ 1,303,397</b>
<b>% Gains/(Losses) in 2022</b>	<b>13.76%</b>	<b>27.63%</b>	<b>15.05%</b>

**BCRFF Portfolio Status as of 12/31/2022**

Description	Opportunity Fund, LP	INOF-III Fund LLC	Total
<b>FUND RESULTS INCEPTION THROUGH 12/31/2022</b>			
<b>Beaver County Retirement Fund Contributions:</b>			
Net Contributions as of 12/31/2021	\$ 7,847,873.51	\$ 810,103.76	\$ 8,657,977.27
Contributions in Fiscal Year 2022	-	-	-
<b>Total Net Contributions as of 12/31/2022</b>	<b>\$ 7,847,874</b>	<b>\$ 810,104</b>	<b>\$ 8,657,977</b>
<b>Fund Gains/(Losses) Inception through 12/31/2022:</b>			
<b>Gains /(Losses):</b>			
Distribution of Gain from the Opportunity Fund	410,939	-	410,939
<b>Total Realized Gains /(Losses)</b>	<b>\$ 410,939.00</b>	<b>\$ -</b>	<b>\$ 410,939.00</b>
<b>Fund Gains/(Losses) Inception through 12/31/2022:</b>			
<b>Fair Value Adjustments:</b>			
Novian Health Series A Preferred Stock	\$ 1,556,898	\$ 609,527	\$ 2,166,425
Propel Series B Convertible Preferred Stock	(18,279)	(3,041)	(21,320)
Vizsafe Series A Preferred Stock	2,818,996	241,702	3,060,698
Cognition Therapeutics Series B Preferred Stock	(10,406)	-	(10,406)
PennAlt Organics Preferred Series A & Warrants	(288,251)	-	(288,251)
Rabble Holdings, Inc. Series A Preferred Stock	37,776	-	37,776
Wenzel Spine, Inc. Series B-2 Preferred Stock	761,615	-	761,615
<b>Total Fair Value Adjustments</b>	<b>\$ 4,858,349</b>	<b>\$ 848,188</b>	<b>\$ 5,706,537</b>
<b>Accrued Interest:</b>			
Interest Converted to Equity	\$ 322,573	\$ 58,348	\$ 380,921
FRH Consumer Services (OneLogos) Note	97,787	34,340	132,127
Novian Health Convertible Note	103,970	-	103,970
Propel IT	96,902	-	96,902
Rable Holdings	28,598	-	28,598
Wenzel Spine	97,487	-	97,487
<b>Total Accrued Interest through 12/31/2022</b>	<b>\$ 747,317</b>	<b>\$ 92,688</b>	<b>\$ 840,005</b>
<b>Total Gains/(Losses) through 12/31/2022</b>	<b>\$ 6,016,605</b>	<b>\$ 940,876</b>	<b>\$ 6,957,481</b>
<b>% Total Gains/(Losses) through 12/31/2022</b>	<b>76.67%</b>	<b>116.14%</b>	<b>80.36%</b>
Fund Fees and Third Party Professional Expenses through 12/31/2022	(1,320,633)	(105,233)	(1,425,866)
<b>Net Gains/(Losses) through 12/31/2022</b>	<b>\$ 4,695,972</b>	<b>\$ 835,643</b>	<b>\$ 5,531,614</b>
<b>% Net Gains/(Losses) through 12/31/2022</b>	<b>59.84%</b>	<b>103.15%</b>	<b>63.89%</b>
<b>Portfolio Value Including Fees and Expenses (Assets at Market)</b>	<b>\$ 12,132,906</b>	<b>\$ 1,645,746</b>	<b>\$ 13,778,653</b>

Note: The Distribitons of Gains of \$410,939 are not included in the Total Portfolio Value.